VRTX
HealthcareVertex Pharmaceuticals Incorporated
$448.80
$-3.33 (-0.74%)
Jan 5, 2026
Price History (1Y)
Analysis
Vertex Pharmaceuticals Incorporated is a biotechnology company in the healthcare sector with a market capitalization of $115.07 billion and annual revenue of $11.72 billion. It employs approximately 6,100 individuals worldwide. The company's financial health indicates strong profitability, with gross margin at 52.7%, operating margin at 40.3%, and profit margin at 31.3%. Vertex also demonstrates solid returns on equity (22.3%) and assets (12.0%), while maintaining a debt to equity ratio of 10.59. The company has significant cash reserves ($6.29 billion) but also carries debt of $1.83 billion. Vertex's valuation is reflected in its price-to-earnings ratios, with a trailing twelve months P/E of 31.85 and forward P/E of 22.18. The company's revenue growth rate stands at 11.0% year-over-year, while earnings growth is slightly lower at 4.7%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $115.07B
- P/E Ratio
- 31.85
- 52-Week High
- $519.68
- 52-Week Low
- $362.50
- Avg Volume
- 1.34M
- Beta
- 0.31
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 6,100